OBJECTIVE: To present the results of the first 2 years of a human papillomavirus (HPV) test-based screening programme outside the research context. DESIGN: Population-based cohort study. SETTING: A cervical service screening programme in Italy. POPULATION: Women aged 25-64 years invited to screening from April 2009 to April 2011. METHODS: Eligible women were invited to undergo an HPV test: those with a negative HPV test went on to the next screening episode; those with a positive HPV went on to triage with a Pap smear. Women with positive cytology (i.e. positive for atypical squamous cells of undetermined significance or worse, ASC-US+) were referred to colposcopy, whereas those with negative cytology were referred to repeat HPV testing 1 year later. MAIN OUTCOME MEASURES: Participation rate, positivity at HPV and at triage, referral rate to colposcopy, positive predictive value for cervical intraepithelial neoplasia grade 2+ (CIN2+) at colposcopy, and detection rate for CIN2+. RESULTS: Participation increased compared with the previous Pap programme (60.6 versus 43.9%). The HPV positivity rate was 7.0; 39.6% of Pap smears were scored as positive, and therefore 2.8% of the women screened were referred for immediate colposcopy. The compliance of women who scored positive for HPV and negative for Pap for repeat HPV testing at 12 months was 78.6%, and the HPV positivity rate was 56.6%. The overall referral rate to colposcopy was 4.6%. The overall detection rate for CIN2+ was 4.5 versus 1.5% of the Pap programme (25-34 years, 8.2%; 35+ years, 3.6%). CONCLUSIONS: Compared with the traditional Pap test, the HPV programme recorded a higher response to invitation and an increased DR for CIN2+. The most critical aspects were the reading of cytology in women that were positive for HPV and the increased workload at colposcopy.
OBJECTIVE: To present the results of the first 2 years of a human papillomavirus (HPV) test-based screening programme outside the research context. DESIGN: Population-based cohort study. SETTING: A cervical service screening programme in Italy. POPULATION: Women aged 25-64 years invited to screening from April 2009 to April 2011. METHODS: Eligible women were invited to undergo an HPV test: those with a negative HPV test went on to the next screening episode; those with a positive HPV went on to triage with a Pap smear. Women with positive cytology (i.e. positive for atypical squamous cells of undetermined significance or worse, ASC-US+) were referred to colposcopy, whereas those with negative cytology were referred to repeat HPV testing 1 year later. MAIN OUTCOME MEASURES: Participation rate, positivity at HPV and at triage, referral rate to colposcopy, positive predictive value for cervical intraepithelial neoplasia grade 2+ (CIN2+) at colposcopy, and detection rate for CIN2+. RESULTS: Participation increased compared with the previous Pap programme (60.6 versus 43.9%). The HPV positivity rate was 7.0; 39.6% of Pap smears were scored as positive, and therefore 2.8% of the women screened were referred for immediate colposcopy. The compliance of women who scored positive for HPV and negative for Pap for repeat HPV testing at 12 months was 78.6%, and the HPV positivity rate was 56.6%. The overall referral rate to colposcopy was 4.6%. The overall detection rate for CIN2+ was 4.5 versus 1.5% of the Pap programme (25-34 years, 8.2%; 35+ years, 3.6%). CONCLUSIONS: Compared with the traditional Pap test, the HPV programme recorded a higher response to invitation and an increased DR for CIN2+. The most critical aspects were the reading of cytology in women that were positive for HPV and the increased workload at colposcopy.
Authors: Paolo Giorgi Rossi; Simonetta Bisanzi; Elena Allia; Alessandra Mongia; Francesca Carozzi; Anna Gillio-Tos; Laura De Marco; Guglielmo Ronco; Daniela Gustinucci; Annarosa Del Mistro; Helena Frayle; Anna Iossa; Giulia Fantacci; Giampaolo Pompeo; Elena Cesarini; Simonetta Bulletti; Basilio Passamonti; Martina Rizzi; Maria Gabriella Penon; Alessandra Barca; Maria Benevolo Journal: J Clin Microbiol Date: 2017-01-18 Impact factor: 5.948
Authors: S Gori; J Battagello; D Gustinucci; C Campari; M Zorzi; H Frayle; B Passamonti; G Sartori; S Bulletti; C Fodero; E Cesarini; R Faggiano; A Del Mistro Journal: BJOG Date: 2021-01-12 Impact factor: 6.531
Authors: Christine Bergeron; Paolo Giorgi-Rossi; Frederic Cas; Maria Luisa Schiboni; Bruno Ghiringhello; Paolo Dalla Palma; Daria Minucci; Stefano Rosso; Manuel Zorzi; Carlo Naldoni; Nereo Segnan; Massimo Confortini; Guglielmo Ronco Journal: J Natl Cancer Inst Date: 2015-01-07 Impact factor: 13.506
Authors: P Giorgi Rossi; C Fortunato; P Barbarino; S Boveri; S Caroli; A Del Mistro; A Ferro; C Giammaria; M Manfredi; T Moretto; A Pasquini; M Sideri; M C Tufi; C Cogo; E Altobelli Journal: Br J Cancer Date: 2015-01-29 Impact factor: 7.640
Authors: Roosmarijn Luttmer; Lise M A De Strooper; Maaike G Dijkstra; Johannes Berkhof; Peter J F Snijders; Renske D M Steenbergen; Folkert J van Kemenade; Lawrence Rozendaal; Theo J M Helmerhorst; René H M Verheijen; W Abraham Ter Harmsel; W Marchien van Baal; Peppino G C M Graziosi; Wim G V Quint; Johan W M Spruijt; Dorenda K E van Dijken; Daniëlle A M Heideman; Chris J L M Meijer Journal: Br J Cancer Date: 2016-07-14 Impact factor: 7.640
Authors: Annarosa Del Mistro; Helena Frayle; Antonio Ferro; Gianpiero Fantin; Emma Altobelli; Paolo Giorgi Rossi Journal: Prev Med Rep Date: 2016-12-23
Authors: A Boers; R P Bosgraaf; R W van Leeuwen; E Schuuring; D A M Heideman; L F A G Massuger; V M J Verhoef; J Bulten; W J G Melchers; A G J van der Zee; R L M Bekkers; G B A Wisman Journal: Br J Cancer Date: 2014-07-17 Impact factor: 7.640